← back to search

Enrique Rivas

Sanofi (Mexico) · MX
Area of research
Epidemiology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Mosquito-borne diseases and control, SARS-CoV-2 and COVID-19 Research, Psoriasis: Treatment and Pathogenesis, and Virology and Viral Diseases.
h-index
13
citations
3,357
works
24
NIH funding
—
primary concept
Medicine
email
enrique.rivas@sanofi.com

Recent publications

Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
The Lancet Infectious Diseases 2020cited by 75position: middledoi
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
New England Journal of Medicine 2014cited by 1,952position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alexander Karpov · Novartis (Switzerland)1 papers (2014–2014)Silvia Helou · Novartis (Switzerland)1 papers (2014–2014)Stephen K. Tyring · The University of Texas at Austin1 papers (2014–2014)Kristian Reich · Universität Hamburg1 papers (2014–2014)Sanjay Gurunathan · Sanofi (United States)1 papers (2020–2020)Theodore S. Steiner · University of British Columbia1 papers (2020–2020)Rayo Morfín‐Otero · Universidad de Guadalajara1 papers (2020–2020)Kim Papp · Goethe University Frankfurt1 papers (2014–2014)Mark G. Martens · Drexel University1 papers (2020–2020)— · 1 papers (2014–2014)Boni E. Elewski · University of Alabama at Birmingham1 papers (2014–2014)Christine Rehm · Sanofi (France)1 papers (2020–2020)— · 1 papers (2014–2014)— · 1 papers (2014–2014)Josh Chen · Vertex Pharmaceuticals (United States)1 papers (2020–2020)Guy de Bruyn · Sanofi (United States)1 papers (2020–2020)Mark Lebwohl · Mount Sinai Hospital1 papers (2014–2014)Carlos Fernando de Magalhães Francesconi · Universidade Federal do Rio Grande do Sul1 papers (2020–2020)Richard Gesser · Sanofi (United States)1 papers (2020–2020)David Gordon · National Health and Medical Research Council1 papers (2020–2020)